Profile data is unavailable for this security.
About the company
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. It also provides Expresse service assurance and CloudCheck WiFi experience management solutions.
- Revenue in USD (TTM)14.23bn
- Net income in USD5.69bn
- Incorporated1988
- Employees10.37k
- LocationRegeneron Pharmaceuticals Inc777 Old Saw Mill River RoadTARRYTOWN 10591United StatesUSA
- Phone+1 (781) 370-5000
- Websitehttps://www.regeneron.com/
Mergers & acquisitions
| Acquired company | REGN:NSQ since announced | Transaction value |
|---|---|---|
| Checkmate Pharmaceuticals Inc | -13.26% | 255.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Iqvia Holdings Inc | 14.14bn | 1.16bn | 43.38bn | 82.00k | 38.85 | 8.11 | 18.97 | 3.07 | 5.99 | 5.99 | 72.98 | 28.68 | 0.5847 | -- | 5.71 | 178,936.70 | 4.81 | 1.77 | 6.06 | 2.14 | 34.42 | 34.30 | 8.23 | 3.64 | -- | 4.95 | 0.7046 | 0.00 | 22.14 | 15.28 | 246.24 | 68.08 | 31.30 | -- |
| McKesson Corporation | 268.45bn | 1.40bn | 50.99bn | 58.00k | 37.74 | -- | 22.63 | 0.19 | 9.40 | 9.40 | 1,782.81 | -13.92 | 4.29 | 12.92 | 13.39 | 4,628,380.00 | 2.50 | -0.7548 | 9.44 | -2.38 | 4.89 | 5.24 | 0.5822 | -0.2014 | 0.5483 | 43.92 | 1.34 | -- | 10.80 | 5.86 | 124.66 | -26.44 | -0.9799 | 9.71 |
| Moderna Inc | 23.00bn | 14.06bn | 66.95bn | 2.70k | 5.22 | 3.73 | 4.66 | 2.91 | 32.80 | 32.80 | 53.79 | 45.88 | 1.09 | 3.18 | 9.76 | 8,516,667.00 | 66.62 | 41.17 | 105.90 | 66.78 | 82.29 | -- | 61.12 | 52.35 | 1.71 | -- | 0.0407 | 0.00 | 2,199.12 | 179.44 | 1,733.33 | -- | 53.67 | -- |
| Regeneron Pharmaceuticals Inc | 14.23bn | 5.69bn | 67.82bn | 10.37k | 12.43 | 3.29 | 11.33 | 4.77 | 50.07 | 50.07 | 125.24 | 188.93 | 0.5844 | 1.02 | 2.34 | 1,372,184.00 | 23.36 | 25.64 | 27.13 | 29.99 | 84.97 | 88.51 | 39.97 | 39.11 | 4.39 | 11.87 | 0.1155 | -- | 89.14 | 27.02 | 129.86 | 55.24 | 1.52 | -- |
| Vertex Pharmaceuticals Incorporated | 8.35bn | 3.19bn | 76.64bn | 3.90k | 24.17 | 6.41 | 22.99 | 9.18 | 12.37 | 12.37 | 32.33 | 46.61 | 0.6007 | 2.88 | 7.38 | 2,141,135.00 | 22.98 | 18.01 | 27.29 | 21.87 | 88.13 | 87.77 | 38.26 | 29.17 | 4.36 | 28.00 | 0.0389 | 0.00 | 22.06 | 34.79 | -13.63 | -- | 32.96 | -- |
| Gilead Sciences, Inc. | 27.52bn | 4.14bn | 77.71bn | 14.40k | 18.90 | 3.84 | 12.50 | 2.82 | 3.28 | 3.28 | 21.81 | 16.14 | 0.4206 | 4.11 | 6.66 | 1,910,764.00 | 6.28 | 8.35 | 7.37 | 10.02 | 75.59 | 79.56 | 14.93 | 22.22 | 1.27 | 6.69 | 0.5646 | 58.76 | 10.60 | -2.12 | 4,960.98 | -14.34 | -4.99 | 9.07 |
| Zoetis Inc | 8.00bn | 2.09bn | 79.37bn | 12.10k | 38.48 | 17.35 | 31.18 | 9.93 | 4.41 | 4.41 | 16.85 | 9.77 | 0.5744 | 1.18 | 6.50 | 660,743.80 | 15.00 | 13.79 | 18.40 | 16.04 | 70.44 | 68.75 | 26.12 | 23.94 | 1.46 | 11.64 | 0.5894 | 22.53 | 16.49 | 9.73 | 24.36 | 19.93 | 17.17 | 20.72 |
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2022 | 9.14m | 8.46% |
| The Vanguard Group, Inc.as of 12 Apr 2022 | 8.16m | 7.55% |
| BlackRock Fund Advisorsas of 31 Mar 2022 | 6.48m | 6.00% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2022 | 5.95m | 5.51% |
| SSgA Funds Management, Inc.as of 31 Mar 2022 | 5.13m | 4.75% |
| JPMorgan Investment Management, Inc.as of 31 Mar 2022 | 3.70m | 3.42% |
| Wellington Management Co. LLPas of 31 Mar 2022 | 2.89m | 2.68% |
| Dodge & Coxas of 31 Mar 2022 | 2.24m | 2.07% |
| Geode Capital Management LLCas of 31 Mar 2022 | 2.09m | 1.94% |
| Loomis, Sayles & Co. LPas of 30 Jun 2022 | 1.76m | 1.63% |
